Biovector Therapeutics Completes Second Phase I Trial for Nasal Influenza Vaccine, Prepares for Phase III Study in Europe.Business/Medical & Health Editors TOULOUSE, France--(BW HealthWire)--July 5, 2000 Biovector Therapeutics SA, a privately held company privately held company A firm whose shares are held within a relatively small circle of owners and are not traded publicly. specializing in drug delivery systems, today announced positive results from a second Phase I study for a novel nasally administered influenza vaccine influenza vaccine Flu vaccine A vaccine recommended for those at high risk for serious complications from influenza: > age 65; Pts with chronic diseases of heart, lung or kidneys, DM, immunosuppression, severe anemia, nursing home and other chronic-care being developed in cooperation with BioChem Pharma. The vaccine incorporates inactivated inactivated rendered inactive; the activity is destroyed. inactivated viruses treated so that they are no longer able to produce evidence of growth or damaging effect on tissue. influenza antigens with licensed Biovector proprietary delivery technology (SMBV SMBV Shawnee Mission Beach Volleyball (Kansas) (R)/Light-Biovector System), which enables the vaccine to be administered using a nasal spray. This optimized Phase I study demonstrated both safety and immunogenicity immunogenicity /im·mu·no·ge·nic·i·ty/ (-je-nis´it-e) the property enabling a substance to provoke an immune response, or the degree to which a substance possesses this property. . The study endpoints are well above European guidelines for flu approval. Biovector Therapeutics has therefore decided to develop the egg culture flu vaccine as it represents a quicker development at a limited risk. Biovector Therapeutics currently is working to access the vaccine doses necessary for a Phase III study to be performed in Europe. Biovector Therapeutics develops and manufactures drug delivery systems to improve the acceptance, delivery and efficacy of modern vaccines and other therapeutics agents. The company's Biovector technology prolongs the effects of therapeutic products, holds patent-extension opportunities for pharmaceuticals and offers a more convenient form of administering drugs. Biovector's primary focus is on the treatment of infectious diseases and cancer by a curative or prophylactic immunotherapy approach. Biovector Therapeutics concentrates its efforts on the development of modern vaccines, taking into account all the components for an efficient immune response immune response n. An integrated bodily response to an antigen, especially one mediated by lymphocytes and involving recognition of antigens by specific antibodies or previously sensitized lymphocytes. . |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion